AU2001296844B2 - Hedgehog antagonists, methods and uses related thereto - Google Patents

Hedgehog antagonists, methods and uses related thereto Download PDF

Info

Publication number
AU2001296844B2
AU2001296844B2 AU2001296844A AU2001296844A AU2001296844B2 AU 2001296844 B2 AU2001296844 B2 AU 2001296844B2 AU 2001296844 A AU2001296844 A AU 2001296844A AU 2001296844 A AU2001296844 A AU 2001296844A AU 2001296844 B2 AU2001296844 B2 AU 2001296844B2
Authority
AU
Australia
Prior art keywords
hedgehog
gli
cells
gene
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001296844A
Other languages
English (en)
Other versions
AU2001296844C1 (en
AU2001296844A1 (en
Inventor
Henryk Dudek
Irina Karavanov
Carmen Pepicelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of AU2001296844C1 publication Critical patent/AU2001296844C1/en
Publication of AU2001296844A1 publication Critical patent/AU2001296844A1/en
Application granted granted Critical
Publication of AU2001296844B2 publication Critical patent/AU2001296844B2/en
Priority to AU2006230725A priority Critical patent/AU2006230725B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001296844A 2000-10-13 2001-10-15 Hedgehog antagonists, methods and uses related thereto Ceased AU2001296844B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006230725A AU2006230725B2 (en) 2000-10-13 2006-10-20 Hedgehog antagonists, methods and uses related thereto

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24056400P 2000-10-13 2000-10-13
US60/240,564 2000-10-13
PCT/US2001/032100 WO2002030462A2 (en) 2000-10-13 2001-10-15 Hedgehog antagonists, methods and uses related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006230725A Division AU2006230725B2 (en) 2000-10-13 2006-10-20 Hedgehog antagonists, methods and uses related thereto

Publications (3)

Publication Number Publication Date
AU2001296844C1 AU2001296844C1 (en) 2002-04-22
AU2001296844A1 AU2001296844A1 (en) 2002-06-27
AU2001296844B2 true AU2001296844B2 (en) 2006-07-20

Family

ID=22907059

Family Applications (3)

Application Number Title Priority Date Filing Date
AU9684401A Pending AU9684401A (en) 2000-10-13 2001-10-15 Hedgehog antagonists, methods and uses related thereto
AU2001296844A Ceased AU2001296844B2 (en) 2000-10-13 2001-10-15 Hedgehog antagonists, methods and uses related thereto
AU2006230725A Ceased AU2006230725B2 (en) 2000-10-13 2006-10-20 Hedgehog antagonists, methods and uses related thereto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU9684401A Pending AU9684401A (en) 2000-10-13 2001-10-15 Hedgehog antagonists, methods and uses related thereto

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006230725A Ceased AU2006230725B2 (en) 2000-10-13 2006-10-20 Hedgehog antagonists, methods and uses related thereto

Country Status (8)

Country Link
US (2) US20040060568A1 (enExample)
EP (1) EP1387674B1 (enExample)
JP (3) JP5196700B2 (enExample)
AU (3) AU9684401A (enExample)
CA (1) CA2425356C (enExample)
DK (1) DK1387674T3 (enExample)
ES (1) ES2623711T3 (enExample)
WO (1) WO2002030462A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280736C (en) 1997-02-10 2012-05-29 The President And Fellows Of Harvard College Methods for modulating hematopoiesis and vascular growth
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2343335C (en) 1998-09-11 2014-05-27 Biogen, Inc. Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
EP1728797A3 (en) 1999-10-13 2011-03-02 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
JP5196700B2 (ja) * 2000-10-13 2013-05-15 キュリス，インコーポレイテッド ヘッジホッグアンタゴニスト、それらに関する方法及び利用
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
EP1411938B1 (en) 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
KR20050036911A (ko) * 2002-05-09 2005-04-20 싸이토키네틱스, 인코포레이티드 화합물들, 방법 및 조성물
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2005013800A2 (en) * 2003-07-15 2005-02-17 The Johns Hopkins University Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
US20080095761A1 (en) * 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
US20070231828A1 (en) * 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
WO2005042700A2 (en) * 2003-10-20 2005-05-12 The Johns Hopkins University Use of hedgehog pathway inhibitors in small-cell lung cancer
AU2005231692B2 (en) * 2004-03-26 2011-01-27 Curis, Inc. RNA interference modulators of Hedgehog signaling and uses thereof
ZA200701535B (en) * 2004-08-27 2008-12-31 Infinity Pharmaceuticals Inc Cyclopamine analogues and methods of use thereof
EP2316832B1 (en) 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
US7625759B2 (en) 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP5473334B2 (ja) 2005-12-23 2014-04-16 ジーランド ファーマ アクティーゼルスカブ 修飾リジン模倣化合物
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
EP2007428A2 (en) * 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
CA2650338C (en) * 2006-04-27 2013-04-16 Illinois Tool Works Inc. Pan chiller system with single state coolant
WO2007136250A2 (en) * 2006-05-24 2007-11-29 Stichting Voor De Technische Wetenschappen A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US7648994B2 (en) 2007-03-07 2010-01-19 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
EP2134719B1 (en) 2007-03-07 2013-07-17 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
US8669243B2 (en) 2007-10-30 2014-03-11 The Wistar Institute Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer
WO2009058945A1 (en) 2007-10-30 2009-05-07 The Wistar Institute Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
CA2709399C (en) * 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
JP5326962B2 (ja) * 2009-09-17 2013-10-30 住友大阪セメント株式会社 防汚加工製品及びその製造方法
WO2012170546A1 (en) * 2011-06-06 2012-12-13 University Of Iowa Research Foundation Methods of inhibiting muscle atrophy
RU2490267C2 (ru) * 2010-05-28 2013-08-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Способ получения конъюгата (6-гидрокси-2,5,7,8-тетраметилхроман-2-ил)ацетальдегида с 20-гидроксиэкдизоном и его применение в качестве антиоксидантного средства, ингибирующего процесс перекисного окисления липидов
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
CN104975099A (zh) * 2011-06-02 2015-10-14 诺华股份有限公司 Hedgehog抑制剂治疗的生物标志物
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
JP6233932B2 (ja) 2012-08-30 2017-11-22 国立大学法人広島大学 ＢＢＦ２Ｈ７（ＢＢＦ２ ｈｕｍａｎ ｈｏｍｏｌｏｇｕｅ ｏｎ ｃｈｒｏｍｏｓｏｍｅ７）部分アミノ酸配列を有するペプチドまたはそれに結合する抗体を含む細胞増殖調節用組成物
EP3008170A4 (en) 2013-06-11 2016-11-09 Harvard College SC-CELLS AND COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
WO2018202865A1 (en) 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
CA3081762A1 (en) 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
CA3108275A1 (en) 2018-08-10 2020-02-13 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
EP4189067A4 (en) 2020-07-31 2024-10-23 Vertex Pharmaceuticals Incorporated DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS
AU2022377078A1 (en) 2021-11-01 2024-04-04 Vertex Pharmaceuticals Incorporated Stem cell derived pancreatic islet differentiation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610656B1 (en) * 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6384192B1 (en) * 1993-12-30 2002-05-07 President & Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
US6261786B1 (en) * 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
US6884775B1 (en) * 1993-12-30 2005-04-26 President And Fellows Of Harvard College Methods and compositions for regulating skeletogenic formation
US7060450B1 (en) * 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
CA2184092A1 (en) 1994-02-25 1995-08-31 Thomas M. Jessell Dna encoding the vertebrate homolog of hedgehog, vhh-1, expressed by the notochord, and uses thereof
US6429354B1 (en) * 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
US6946257B1 (en) * 1994-10-07 2005-09-20 Regents Of The University Of California Patched genes and uses related thereto
US6027882A (en) * 1994-10-07 2000-02-22 The Regents Of The University Of California Patched genes and their use for diagnostics
DE69534310T2 (de) * 1994-10-07 2006-04-27 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Ptc gene und ihre verwendung
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US5759811A (en) 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
JPH10215867A (ja) * 1997-02-04 1998-08-18 Asahi Glass Co Ltd タンパク質誘導体、該タンパク質をコードする遺伝子および該タンパク質の製造法
CA2280736C (en) 1997-02-10 2012-05-29 The President And Fellows Of Harvard College Methods for modulating hematopoiesis and vascular growth
WO1999010004A2 (en) 1997-08-29 1999-03-04 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
EP1067939B1 (en) * 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
JP2002524528A (ja) * 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
CA2343335C (en) * 1998-09-11 2014-05-27 Biogen, Inc. Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor
IL142905A0 (en) * 1998-11-02 2002-04-21 Biogen Inc Functional antagonists of hedgehog activity
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
JP2003501395A (ja) 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
US20050080138A1 (en) * 1999-09-16 2005-04-14 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
EP1728797A3 (en) * 1999-10-13 2011-03-02 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
EP1227805B2 (en) 1999-10-14 2011-02-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU4966401A (en) 2000-03-30 2001-10-15 Curis Inc Small organic molecule regulators of cell proliferation
CA2412215A1 (en) * 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
JP5196700B2 (ja) * 2000-10-13 2013-05-15 キュリス，インコーポレイテッド ヘッジホッグアンタゴニスト、それらに関する方法及び利用
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
EP1401469A2 (en) 2001-04-09 2004-03-31 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
FR2834403B1 (fr) * 2001-12-27 2004-02-06 France Telecom Systeme cryptographique de signature de groupe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
References cited in WO 02/30462 *

Also Published As

Publication number Publication date
AU2001296844C1 (en) 2002-04-22
DK1387674T3 (en) 2017-04-10
US8486400B2 (en) 2013-07-16
AU2006230725B2 (en) 2009-01-08
AU2006230725A1 (en) 2006-11-09
JP2009179630A (ja) 2009-08-13
CA2425356C (en) 2015-10-06
JP2004529067A (ja) 2004-09-24
ES2623711T3 (es) 2017-07-12
AU9684401A (en) 2002-04-22
EP1387674B1 (en) 2017-01-18
US20110076286A1 (en) 2011-03-31
CA2425356A1 (en) 2002-04-18
WO2002030462A2 (en) 2002-04-18
JP2008214356A (ja) 2008-09-18
WO2002030462A9 (en) 2003-05-15
WO2002030462A3 (en) 2003-12-04
JP5196700B2 (ja) 2013-05-15
US20040060568A1 (en) 2004-04-01
EP1387674A2 (en) 2004-02-11

Similar Documents

Publication Publication Date Title
AU2001296844B2 (en) Hedgehog antagonists, methods and uses related thereto
US8357368B2 (en) Methods of treating pancreatic or liver cancer using hedgehog antagonists
AU2001296844A1 (en) Hedgehog antagonists, methods and uses related thereto
WO2004020599A2 (en) Hedgehog antagonists, methods and uses related thereto
AU2003231032B2 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU778866B2 (en) Regulators of the PCT or smoothened pathway, compositions and uses related thereto
EP1482928B1 (en) Mediators of hedgehog signaling pathways,compositions and uses related thereto
EP1227805B1 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2005201269B2 (en) Regulators of the PCT or smoothened pathway, compositions and uses related thereto
AU2011224045A1 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 OCT 2006.

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 OCT 2006

MK14 Patent ceased section 143(a) (annual fees not paid) or expired